Fasting Insulin. The Number Your Annual Physical Never Orders.

Glucose comes late. By the time fasting glucose is elevated enough to meet the criteria for prediabetes, insulin resistance has usually been present for years. Sometimes a decade. The pancreas was compensating the entire time, producing more insulin to keep the glucose in normal range. That compensation works, right up until it does not. When it stops working, we call what emerges prediabetes, then type 2 diabetes. But the compensation itself was the disease. And fasting insulin measures it, years before fasting glucose gives any signal.

The Mechanism

The sequence of metabolic deterioration is rarely taught to patients, even though understanding it changes how they interpret their own lab results.

Insulin resistance develops first. The cells of the liver, skeletal muscle, and adipose tissue become progressively less responsive to insulin’s signaling. Insulin normally binds to receptors on these cells and triggers a cascade that moves glucose transporters to the cell surface, allowing glucose to enter. When those cells are insulin resistant, the signal is blunted. The same amount of insulin produces less glucose clearance.

The pancreas detects rising blood glucose and responds by producing more insulin. For years, sometimes for well over a decade, this compensatory hyperinsulinemia is sufficient to keep fasting and postprandial glucose within the normal reference range. A standard lab report during this period will show normal glucose. The physician notes no abnormality. The patient is told everything looks fine.

During this entire period of compensatory hyperinsulinemia, the elevated circulating insulin is not physiologically inert. High insulin promotes renal sodium retention, which raises blood pressure through increased plasma volume and increased vascular resistance. It activates lipogenic pathways in the liver, driving increased production of VLDL triglycerides. It promotes visceral fat deposition, which itself worsens insulin resistance, creating a self-reinforcing cycle. It contributes to a chronic low-grade inflammatory state through activation of nuclear factor kappa B pathways. And it drives the dyslipidemia pattern most closely associated with cardiovascular risk: elevated triglycerides, low HDL, and increased production of small, dense LDL particles.

That final consequence is the one with the most direct cardiovascular relevance. A man with insulin resistance and compensatory hyperinsulinemia will typically have a lipid panel showing triglycerides between 150 and 300 mg/dL, HDL below 40 mg/dL, and LDL in a normal or near-normal range. His physician may note “borderline triglycerides” and advise dietary changes. What that lipid pattern actually reflects, when combined with a high fasting insulin, is an ApoB-elevated, small-dense-LDL-predominant phenotype with substantially higher cardiovascular risk than the LDL-C value suggests.

The fasting insulin test measures the compensation directly and provides early warning of this entire cascade while it is still reversible.

What the Evidence Shows

The evidence connecting elevated fasting insulin to future cardiovascular risk is substantial, though the research is of somewhat lower uniformity than the ApoB and LDL literature, which is why the honesty rating for this article is 4/Promising rather than Solid. 4 / Promising

The METSIM study (Metabolic Syndrome in Men), a Finnish prospective cohort of 10,197 men followed over approximately 7 years, found that elevated fasting insulin independently predicted incident cardiovascular events after adjustment for traditional risk factors including LDL, blood pressure, smoking, and age. Men in the highest quartile of fasting insulin had a significantly elevated cardiovascular event rate compared to men in the lowest quartile, even when fasting glucose was normal. (Stancakova et al., Diabetologia, 2017, doi: 10.1007/s00125-017-4401-1)

The Paris Prospective Study, which followed approximately 7,000 working men over 11 years, established that fasting insulin predicted coronary heart disease mortality independently of glucose tolerance status. This study, published in the early 1990s by Fontbonne et al. and Eschwege et al., was important because it demonstrated predictive value in a population without diabetes, establishing that insulin, not just glucose, was independently associated with cardiovascular outcomes.

The Atherosclerosis Risk in Communities (ARIC) study, one of the largest US prospective cardiovascular cohorts, documented that insulin resistance, measured by multiple approaches including fasting insulin, predicted incident coronary heart disease in participants without baseline diabetes across a wide range of demographic subgroups. Participants in the highest tertile of insulin resistance had approximately 1.8 times the incident CHD risk of those in the lowest tertile after multivariate adjustment.

It is worth being precise about the limitations here. Most of the evidence for fasting insulin as a cardiovascular predictor comes from observational studies, not from randomized trials. The independent contribution of fasting insulin, after adjustment for the metabolic abnormalities it produces (dyslipidemia, hypertension, elevated ApoB), is more modest than the unadjusted association. Some of fasting insulin’s predictive power is mediated through those downstream effects. This does not make fasting insulin clinically useless. It means fasting insulin is most valuable as an upstream marker that tells you the downstream abnormalities are in process, potentially before they are detectable by standard testing.

The HOMA-IR calculation (Homeostatic Model Assessment of Insulin Resistance), which is derived by multiplying fasting glucose in mmol/L by fasting insulin in mIU/L and dividing by 22.5, is the most widely studied mathematical formulation of insulin resistance from these two measurements. A HOMA-IR above 2.0 to 2.5 is generally considered consistent with significant insulin resistance in research contexts, though laboratory reference ranges vary.

Insulin Resistance, Insulin Sensitivity, and Beta-Cell Exhaustion

These three concepts are related but distinct, and conflating them is the most common interpretive error clinicians and patients make with fasting insulin results.

Insulin resistance means the body’s target tissues, primarily liver, skeletal muscle, and adipose, do not respond normally to insulin’s signal. More insulin is required to produce the same degree of glucose clearance. The pancreas is still capable of meeting that demand, so it compensates by secreting more. The result is high circulating insulin with normal or near-normal blood glucose. This is the phase fasting insulin is best positioned to detect.

Insulin sensitivity is the inverse of insulin resistance. A highly insulin-sensitive person clears glucose efficiently with a small insulin signal. Their fasting insulin tends to be low, often below 5 uIU/mL, and their pancreas is not under stress. Regular aerobic exercise is the most potent driver of skeletal muscle insulin sensitivity; it upregulates GLUT4 transporter expression and improves mitochondrial function in a way that reduces the insulin requirement for a given glucose load. 5 / Solid

Beta-cell exhaustion represents the breakdown of compensation. After years or decades of compensatory hyperinsulinemia, the beta cells of the pancreatic islets may progressively lose their capacity to sustain the elevated output. When this happens, insulin secretion falls even as insulin resistance persists. Fasting glucose begins to rise, first into the prediabetic range of 100-125 mg/dL, eventually into overt diabetes. Crucially, fasting insulin at this stage may be normal or even low, which can create a falsely reassuring impression if interpreted in isolation.

This is why reading fasting insulin alongside fasting glucose, rather than in isolation, is the correct interpretive approach.

A high fasting insulin with normal fasting glucose signals active insulin resistance with intact pancreatic compensation. The metabolic damage is accumulating but the system is still compensating. This is the most actionable finding because the trajectory is still reversible.

A high fasting insulin with elevated fasting glucose (100-125 mg/dL) signals insulin resistance with early failure of compensation. The pancreas is still trying but no longer succeeding at maintaining normal glucose. Prediabetes is present and the insulin elevation may still be detectable before it falls.

A normal or low fasting insulin with elevated fasting glucose, particularly when glucose is above 126 mg/dL, may indicate beta-cell exhaustion, the pancreas has already lost substantial secretory capacity. This pattern is more consistent with established type 2 diabetes where the compensatory phase has passed. In this scenario, fasting insulin loses some of its utility as an early warning marker because the “warning” is effectively the overt glucose elevation itself.

Understanding which phase a person is in changes the clinical conversation significantly. Someone with a fasting insulin of 18 uIU/mL and a fasting glucose of 88 mg/dL is in a very different position than someone with a fasting insulin of 9 uIU/mL and a fasting glucose of 118 mg/dL, even though neither has a diabetes diagnosis. The first has a high-functioning but overworked pancreas and a long window of opportunity. The second may be approaching the limit of pancreatic compensation and has less runway. The fasting insulin value alone, without the glucose context, does not convey this distinction.

How to Test Correctly

The quality of a fasting insulin result depends substantially on how the test is collected. The measurement is more sensitive to pre-analytical variation than fasting glucose, and a result drawn under suboptimal conditions can be misleading.

The fast itself: Eight to ten hours of fasting before the draw is the standard requirement. Water is allowed and encouraged. Coffee and tea, even black, should be avoided on the morning of the draw because caffeine has been shown to acutely stimulate cortisol release, which in turn promotes hepatic glucose production and can transiently raise insulin levels. The fast should be continuous, waking up, consuming nothing except water, and going directly to the laboratory. 4 / Promising

Timing of the draw: Morning draws, ideally before 10 AM, are strongly preferred. Cortisol follows a diurnal pattern with its highest levels in the early morning hours, suppressing insulin somewhat during the nocturnal fast. By mid-morning, cortisol begins to fall, and insulin may rise in anticipation of feeding even before food is consumed. Draws taken late in the morning or in the afternoon, particularly if the person has been awake and active for many hours, may not reflect the true fasting nadir. A draw at 7 AM after an overnight fast gives a more reliable and reproducible baseline than one taken at noon.

Exercise before the draw: Vigorous exercise in the 24 hours before the draw can acutely lower fasting insulin by improving skeletal muscle insulin sensitivity and depleting muscle glycogen, which increases glucose uptake without insulin at the drawing time. This is not necessarily a problem if exercise is a stable habit and the test is meant to reflect the person’s true baseline metabolic state. However, someone who exercises intensely the evening before their blood draw after weeks of sedentary behavior will produce a result that underestimates their typical fasting insulin. For the most representative baseline, consistent exercise habits are more important than any specific rule about the 24 hours preceding the draw.

Laboratory variability: Insulin assays are not standardized across laboratories the way glucose assays are. Different manufacturers use different antibodies, and the same blood sample tested at two different laboratories can produce results that differ by 20-30% or more. This is not a reason to avoid the test; it is a reason to interpret the result within the reference range of the specific laboratory used, and to use the same laboratory for serial monitoring over time. If a person tests at LabCorp in January and Quest in April, the two numbers are not directly comparable even if the patient is otherwise identical. Requesting the same laboratory for follow-up testing is a practical step that improves the clinical utility of longitudinal tracking.

The HOMA-IR calculation in practice: When both fasting insulin and fasting glucose are drawn from the same sample, HOMA-IR provides a more substantial index of insulin resistance than either value alone. The formula using conventional US units is: HOMA-IR = (fasting glucose in mg/dL × fasting insulin in uIU/mL) ÷ 405. Using SI units: HOMA-IR = (fasting glucose in mmol/L × fasting insulin in mIU/L) ÷ 22.5. A HOMA-IR above 2.0 to 2.5 is the most widely cited threshold for clinically significant insulin resistance in research literature. A value above 3.5 represents substantial insulin resistance, and values above 5.0 are associated with metabolic syndrome and significantly elevated cardiometabolic risk. 5 / Solid Because HOMA-IR combines the information from both measurements, it is generally preferred over fasting insulin alone for characterizing insulin resistance, though it requires that both tests be drawn at the same fasting visit, which they should be regardless.

What Optimal Looks Like

Most laboratory reference ranges for fasting insulin are set wide, often to 25 uIU/mL or higher. This upper limit is set to capture clinically overt hyperinsulinemia requiring medical attention. It does not represent metabolic health.

Epidemiological data from populations with very low rates of metabolic syndrome suggest that metabolically healthy individuals typically have fasting insulin levels below 5 to 7 uIU/mL. The clinical significance thresholds, based on the research literature, are roughly as follows: below 7 uIU/mL is consistent with good insulin sensitivity; 7 to 10 uIU/mL warrants monitoring and attention to the lifestyle factors that drive insulin resistance; above 10 uIU/mL with normal glucose signals active insulin resistance that has not yet crossed the diagnostic threshold for prediabetes; above 15 uIU/mL makes the conversation about intervention clinically urgent.

These thresholds are not universally standardized across clinical guidelines, which is part of why fasting insulin has not yet achieved the same guideline status as fasting glucose or HbA1c for metabolic screening. The measurement is valuable despite this; the interpretation requires clinical context.

Fasting insulin is one of the few cardiovascular risk markers that responds rapidly and measurably to behavioral intervention. Reduction in refined carbohydrate intake reduces postprandial insulin demand and lowers fasting levels within weeks. Increased aerobic physical activity improves skeletal muscle insulin sensitivity, reducing the compensatory insulin required to maintain normal glucose. Improved sleep quality, specifically addressing sleep duration below 6 hours and sleep apnea when present, has been shown to reduce fasting insulin in multiple small trials. Visceral fat loss, through any sustainable means, reduces the primary driver of hepatic and peripheral insulin resistance. A man who reduces his fasting insulin from 18 to 8 uIU/mL over four months has made a measurable change in his cardiovascular risk trajectory, even if his LDL has not moved.

What to Do This Week

1. At your next clinic visit, ask specifically for fasting insulin to be added to your lab order. The exact language is: “I would like to add fasting insulin to assess for insulin resistance.” Most physicians will order it without objection. It requires the same overnight fast as fasting glucose, so it can be drawn at the same time.

2. If you cannot access your physician soon, fasting insulin is available through direct-to-consumer laboratory services in most US states. Quest Diagnostics and LabCorp both offer it independently, typically for under $40 without insurance.

3. If your result comes back above 10 uIU/mL, bring it to your physician with a specific question: does this change my ApoB interpretation, my blood pressure management, or my overall cardiovascular risk assessment? You are asking for the downstream implications, not just the number in isolation.

4. Check your waist circumference today. Above 40 inches in men is the single most accessible proxy for visceral adiposity and insulin resistance. It is not a diagnosis, but it is a reliable reason to measure fasting insulin, and knowing the number clarifies whether to take the waist circumference seriously.

5. If your fasting insulin is elevated, consider tracking it every three to four months as you make dietary and activity changes. It is a responsive marker. Seeing it move is the most direct available evidence that the metabolic interventions you are making are having the intended effect.

The annual physical orders what it has always ordered. Fasting insulin was never added to the standard panel because standards evolve slowly and the evidence was not yet established when those panels were designed. The evidence is now established. The test is inexpensive. The information changes the clinical picture for a large fraction of the men who have never had it drawn.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.